SCHEMBL29823331

SCHEMBL29823331

c1ccc(CCN(Cc2cccc(CNCc3ccccn3)c2)Cc2c[nH]cn2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 1/20 0.42
KDM4E B2RXH2 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LIN28A Q9H9Z2 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
SMARCA2 P51531 1/20 0.38
ATM Q13315 1/20 0.37
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
DRD2 P14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1882890 1.00 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ACYP2D6CYP2C9
SCHEMBL1875063 0.91 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AKDM4EL3MBTL1
SCHEMBL30338237 0.91 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AKDM4EL3MBTL1
SCHEMBL4428290 0.83 ALDH1A1 (0.53) ALDH1A1MEN1KMT2ACYP2D6CYP2C9
SCHEMBL1874485 0.77 CYP2D6 (0.41) ALDH1A1MEN1KMT2ACYP2D6CYP2C9
SCHEMBL3389096 0.76 CYP2D6 (0.61) ALDH1A1CYP2D6CYP2C9CYP2C19RECQL
SCHEMBL14931741 0.75 KMT2A (0.68) ALDH1A1MEN1KMT2AKDM4EL3MBTL1
SCHEMBL30225577 0.75 KMT2A (0.68) ALDH1A1MEN1KMT2AKDM4EL3MBTL1
SCHEMBL5575878 0.73 KDM4E (0.66) ALDH1A1MEN1KMT2ACYP2D6CYP2C19
SCHEMBL30338402 0.73 KDM4E (0.66) ALDH1A1MEN1KMT2ACYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025230907-A1 A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-11-06 WO disclosed
EP-4308694-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS Magenta Therapeutics, Inc. (US) 2024-01-24 EP disclosed
CN-115997009-A Methods and compositions for in vivo transduction of hematopoietic stem and progenitor cells 美真达治疗公司 2023-04-21 CN disclosed
EP-4143302-A1 METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO Magenta Therapeutics, Inc. (US) 2023-03-08 EP disclosed
WO-2022197776-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS Magenta Therapeutics, Inc. (US) 2022-09-22 WO disclosed
EP-4051298-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENTOR CELLS Magenta Therapeutics, Inc. (US) 2022-09-07 EP disclosed